Background: Autologous serum skin test (ASST) is an in vivo test to demonstrate circulating endogenous proinflammatory or wheal-inducing factors in urticaria patients. While ASST was negative in a patient with solar urticaria and in a patient with localized heat urticaria, test results turned to positive when performed with visible light-irradiated and heated serums, respectively. These data suggest that some factors and/or antibodies in serum may be activated or inhibited with different factors. We aimed to investigate whether or not ASST results change when performed with narrowband ultraviolet B (UVB)-irradiated serum.
Materials And Methods: Seventy-seven patients with chronic idiopathic urticaria underwent ASST twice in consecutive days. The second ASST was performed with narrowband UVB-irradiated serum. The results of the first and second ASSTs were compared.
Results: The first ASST results were positive in 46 (59.7%) patients. ASST results reversed oppositely in 36 (46.8%) patients, turned from negative to positive in 19 patients, and turned from positive to negative in 17 patients when performed with narrowband UVB-irradiated serum.
Conclusion: Our results suggest that narrowband UVB may have modifying effects on some wheal-inducing factors and/or antibodies. On which factors in serum narrowband UVB has effects may be investigated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-4632.2012.05511.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fractional CO laser combined with narrow-band ultraviolet B (NB-UVB) phototherapy versus NB-UVB monotherapy in vitiligo patients: prospective, self-controlled, and randomized trial.
Lasers Med Sci
January 2025
Department of Dermatology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Vitiligo is a chronic depigmenting condition that causes amelanotic macules and patches on the skin. Despite various treatment options, treating vitiligo is a challenge. This study aimed to evaluate the combination of laser CO fractional and narrow-band ultraviolet B (NB-UVB) versus NB-UVB monotherapy in vitiligo patients.
View Article and Find Full Text PDFUltra-high-frequency Ultrasound in the Objective Assessment of Chlormethine Gel Efficacy: A Case Report.
Acta Dermatovenerol Croat
November 2024
Agata Janowska, MD, Department of Dermatology, , University of Pisa, Via Roma 67, 56126, Pisa, Italy; Phone: +39 050 992436, Fax: +39 050 992556,
Mycosis fungoides (MF) represent the most frequent form of cutaneous T-cell lymphoma (CTCL). Chlormethine gel has been approved as first-line therapy in MF. The classification of early forms of MF is clinically and histologically complex even for experienced clinicians.
View Article and Find Full Text PDFCombination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study.
Clin Cosmet Investig Dermatol
December 2024
Department of Dermatology, Air Force Medical Center, PLA, Beijing, People's Republic of China.
Background: Vitiligo is a chronic autoimmune disease manifested by depigmented patches of skin devoid of melanocytes. Baricitinib, a JAK inhibitor selectively targeting JAK1/2, has shown preliminary efficacy for vitiligo. We aimed to assess the efficacy and tolerability of combination therapy with baricitinib and narrowband UV-B (NB-UVB) to treat active nonsegmental vitiligo (NSV).
View Article and Find Full Text PDFNew-onset cutaneous lichen planus following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination.
SAGE Open Med Case Rep
December 2024
Department of Dermatology, College of Medicine, University of Saskatchewan, Regina, SK, Canada.
We report a 56-year-old male who developed cutaneous lichen planus (LP) following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination. Multiple topical and systemic therapies were tried with limited success; however, partial improvement was observed with narrow-band UVB (NB-UVB) phototherapy. This report adds to the growing evidence of new-onset LP following COVID-19 vaccination and underscores the need for careful reporting, monitoring, and management of vaccine-related adverse effects.
View Article and Find Full Text PDFResponse to ritlecitinib with or without narrow-band UVB add-on therapy in patients with active nonsegmental vitiligo: results from a phase 2b extension study.
J Am Acad Dermatol
December 2024
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:
Background: Ritlecitinib demonstrated efficacy in a phase 2b trial of nonsegmental vitiligo.
Objective: To evaluate the efficacy and tolerability of ritlecitinib with add-on narrow-band UVB (nbUVB) phototherapy in patients with nonsegmental vitiligo.
Methods: Following a 24-week, placebo-controlled, dose-ranging period, patients received ritlecitinib 200mg for 4 weeks then 50mg for 20 weeks, with or without nbUVB phototherapy 2x/week.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!